

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

9th January 2023**MAJOR NORTH CAROLINA BASED HEALTHCARE ORGANISATION COMMENCES wheezo[®] REMOTE PATIENT MONITORING (RPM) PROGRAM ONBOARDING.****Highlights:**

- Respiri and Access Telehealth RPM, under the supervision of a Major North Carolina Healthcare Organisation (Client), commence enrolment of patients with Chronic Obstructive Pulmonary Disease (COPD) on the wheezo[®] RPM program.
- Remote Patient Monitoring (RPM) Current Procedural Terminology (CPT) reimbursement claims and revenues to be processed and received within the next few months.
- Respiri to receive recurring revenues per patient per month in addition to device sales.

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory health management is pleased to announce that the existing Major North Carolina Healthcare Organisation client (see ASX announcement dated August 18, 2022) have identified and commenced enrolment of Chronic Obstructive Pulmonary Disease (COPD) patients into the wheezo[®] RPM program.

The program was secured with RPM partner Access Telehealth under the full-service premium model that includes patient engagement and remote monitoring using the Access cloud-based platform, Remotli. The wheezo[®] RPM program is an important clinical addition to patient management aimed at reducing hospital re-admissions that place a healthcare and economic burden on medical institutions and health insurers. Approximately 4% of Americans have COPD (more than 12,500,000) and 8% live with asthma.

More than 150,000 Americans die of COPD¹ every year, which is a death every 4 minutes, making COPD the 3rd principal cause of death behind stroke and ischaemic heart disease and a major burden on healthcare. Hospitalised COPD patients have an 82% lower survival rate in the following 15 years for worsening COPD than people in the general population. Keeping such patients out of hospital through better remote management is therefore a desirable clinical objective and now with the launch of wheezo[®] this is a real possibility. The clinical management objective is for the wheezo[®] RPM program to be a lifelong practice for patients.

RPM Current Procedural Terminology (CPT) reimbursement codes from this program will be processed through Centers for Medicare and Medicaid Services (CMS) and private insurers over the next few months with subsequent revenues flowing to Respiri and Access Telehealth.

¹ COPD deaths - [COPD Statistics & Facts in the US \(2023\) \(cfah.org\)](https://www.cfh.org)

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

The Client manages over 60,000 in-patient admissions and observations, 187,000+ emergency department (ED) visits and almost 2,000,000 outpatient visits per annum. This equates to approximately 25,000 respiratory ED visits and more than 250,000 respiratory outpatient services per annum, many of whom would qualify for enrolment into the wheezo® RPM program.

Establishment of this remote patient program is intended to extend care beyond the clinic and promote improved outcomes and reduce hospitalizations related to respiratory diseases. This is the first time the Client has provided such a program that focuses on respiratory disease intervention using the novel wheezo® device to track and monitor patient physiologic data between clinical visits and after acute care. Under the terms of the original agreement with the Client, Respiri/Access Telehealth are not permitted to publicly announce the name of the Client or Group at this time.

Marjan Mikel, CEO of Respiri said, "What a great way to start 2023 and build on our successes in 2022. After a successful launch of the wheezo® RPM program in 2022, our momentum in the USA continues as existing clients grow wheezo® RPM patient enrolment to drive better health outcomes and health resource optimization whilst we continue to bring new clients on board."

Respiri together with Access Telehealth are in advanced discussions with several other potential wheezo® RPM customers who have recognised the benefits of introducing RPM services as part of patient standard of care.

This announcement has been approved by the Board of Respiri Limited

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

wheezo® is a registered trademark of Respiri Limited.

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

About Respiri Limited

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an international e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US remote patient monitoring market. Its world-first technology detects wheeze, a typical symptom of Asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri created technology optimises how patients in partnership with their physicians manage chronic respiratory conditions. These solutions can help transform the way physicians interact with respiratory patients while they are away from the clinic. wheezo®, is an FDA cleared Class II Medical Device, the respiri™ app (patient-user-interface) and the secure health portal can help different health organisations and providers connect with patients to improve collaboration and help improve respiratory condition management. In the USA, wheezo® can be integrated into Remote Patient Monitoring (RPM) programs and qualifies for RPM Current Procedural Terminology (CPT) reimbursement.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world with respiratory disorders and dramatically reduce hospital admissions and the economic burden of Asthma and COPD. Respiri Limited's operations are based in Melbourne, Australia with offices in New York City, USA.

For additional information about Respiri Limited please visit our corporate website www.respiri.co/au

About wheezo®

Developed in Australia, with the support of an international panel leading respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the intuitive mobile application engages patients to log symptoms and triggers to build a personal profile to share data with healthcare providers so patients and physicians can have more informed discussions in relation to symptoms. The platform has been designed to extend care beyond the clinic which may lead to better health outcomes and improved quality of life for patients.

For information about our product offering in the US including wheezo® please visit www.respiri.co/us

wheezo® is a registered trademark of Respiri Limited.

About Access Telehealth

Access Telehealth is a digital health company dedicated to delivering innovative connected care solutions for management of people living with chronic disease. The Remotli platform uniquely simplifies remote care delivery with patient engagement and productivity driven dashboard tools to support effective patient care and compliance. Automated care-time tracking, and reimbursement reports makes it easy to boost revenue to support vital chronic disease management programs including Remote Physiologic Monitoring, Remote Therapeutic Monitoring, Transitional Care, Chronic Care Management, Telemedicine and more. Focusing on Remote Physiologic Monitoring and virtual care initiatives, the Access Telehealth clinical team delivers patient-centric remote monitoring services to support disease specific chronic care programs for health systems, payors, and providers, to enhance care delivery. www.accessrpm.com/

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.